Gustafsson-Lutz Anna, Bäck Tom, Aneheim Emma, Hultborn Ragnar, Palm Stig, Jacobsson Lars, Morgenstern Alfred, Bruchertseifer Frank, Albertsson Per, Lindegren Sture
Department of Radiation Physics, Institute of Clinical Sciences, The Sahlgrenska Academy, University of Gothenburg, Gula Stråket 2B, 413 45, Gothenburg, Sweden.
Department of Oncology, Institute of Clinical Sciences, The Sahlgrenska Academy, University of Gothenburg, Blå Stråket 2, 413 45, Gothenburg, Sweden.
EJNMMI Res. 2017 Dec;7(1):38. doi: 10.1186/s13550-017-0283-2. Epub 2017 Apr 24.
The aim of this study was to compare the therapeutic efficacy of two different activity levels of the Bi-labeled monoclonal antibody MX35 in an ovarian cancer model. Sixty female BALB/c (nu/nu) mice were inoculated intraperitoneally with human ovarian cancer cells (OVCAR-3). Two weeks later, 40 mice were injected intraperitoneal (i.p.) with 1 ml of Bi-MX35, 3 MBq/mL (n = 20), or 9 MBq/mL (n = 20). An additional 20 mice received unlabeled MX35. Incidence of tumors and ascites was investigated 8 weeks after therapy. Body weight and white blood cell counts were monitored after treatment for possible signs of toxicity.
The tumor-free fraction of the animals treated with 3 MBq/mL of Bi-MX35 was 0.55, whereas that of animals treated with 9 MBq/mL of Bi-MX35 was 0.78. The control group treated with unlabeled MX35 had a tumor-free fraction of 0.15. No significant reduction in white blood cell counts or weight loss was observed.
Tumor growth after i.p. treatment with Bi-MX35 was significantly reduced compared to treatment with unlabeled MX35. Treatment with 9 MBq/mL of Bi-MX35 resulted in higher tumor-free fraction compared with 3 MBq/mL of Bi-MX35, but this difference was not statistically significant. No signs of toxicity were observed in the treated animals.
本研究的目的是比较双标记单克隆抗体MX35在两种不同活性水平下对卵巢癌模型的治疗效果。60只雌性BALB/c（nu/nu）小鼠经腹腔接种人卵巢癌细胞（OVCAR-3）。两周后，40只小鼠腹腔注射1 ml双标记MX35，剂量分别为3 MBq/mL（n = 20）或9 MBq/mL（n = 20）。另外20只小鼠接受未标记的MX35。治疗8周后调查肿瘤和腹水的发生率。治疗后监测体重和白细胞计数，观察是否有中毒迹象。
接受3 MBq/mL双标记MX35治疗的动物无瘤率为0.55，而接受9 MBq/mL双标记MX35治疗的动物无瘤率为0.78。接受未标记MX35治疗的对照组无瘤率为0.15。未观察到白细胞计数显著降低或体重减轻。
与未标记MX35治疗相比，腹腔注射双标记MX35后肿瘤生长显著减少。与3 MBq/mL双标记MX35相比，9 MBq/mL双标记MX35治疗导致更高的无瘤率，但这种差异无统计学意义。在接受治疗的动物中未观察到中毒迹象。
